CNTA Logo

Centessa Pharmaceuticals plc (CNTA) 

NASDAQ
Market Cap
$2.38B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
491 of 774
Rank in Industry
262 of 432

Largest Insider Buys in Sector

CNTA Stock Price History Chart

CNTA Stock Performance

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of …

Insider Activity of Centessa Pharmaceuticals plc

Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $8.26M worth of Centessa Pharmaceuticals plc stock.

On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $3.29M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.

List of Insider Buy and Sell Transactions, Centessa Pharmaceuticals plc

2024-11-13SaleChief Executive Officer
32,023
0.0284%
$18.28$585,419-9.46%
2024-10-25SaleChief Business Officer
11,742
0.0103%
$15.38$180,6280.00%
2024-10-23SaleChief Executive Officer
2,592
0.0023%
$15.32$39,6970.00%
2024-10-22SaleChief Executive Officer
30,203
0.027%
$15.67$473,1690.00%
2024-10-21SaleChief Executive Officer
22,205
0.0196%
$15.80$350,861+1.33%
2024-09-25SaleChief Business Officer
16,619
0.0148%
$15.69$260,724-0.12%
2024-09-20SaleChief Executive Officer
55,000
0.0484%
$16.53$908,985-3.56%
2024-09-10SaleChief Executive Officer
175,000
0.1752%
$16.52$2.89M+9.67%
2024-09-10SaleChief Business Officer
30,000
0.0309%
$17.00$510,000+9.67%
2024-09-09SaleChief Business Officer
25,000
0.0222%
$15.00$375,000+7.10%
2024-08-23SaleChief Executive Officer
46,651
0.0395%
$12.30$573,905+23.35%
2024-08-23SaleChief Business Officer
17,802
0.015%
$12.29$218,792+23.35%
2024-08-22SaleChief Executive Officer
506
0.0004%
$12.23$6,188+29.75%
2024-08-22SaleChief Business Officer
12,198
0.0107%
$12.17$148,430+29.75%
2024-08-21SaleChief Executive Officer
3,674
0.0033%
$12.25$44,989+29.48%
2024-08-20SaleChief Executive Officer
4,169
0.0038%
$12.32$51,368+31.45%
2024-03-25SaleChief People Officer
51,160
0.0541%
$11.88$607,960-6.13%
2024-02-01SaleSVP Regulatory Affairs
4,267
0.0043%
$8.10$34,574+34.89%
2023-09-20SaleSVP Regulatory Affairs
37,484
0.0391%
$6.29$235,688+43.62%
2023-06-01SaleEVP & Chairman of Development
6,500
0.0065%
$4.45$28,949+56.55%

Insider Historical Profitability

<0.0001%
SAHA SAURABHChief Executive Officer
630661
0.479%
$18.11310<0.0001%
Weinhoff Gregory MChief Business Officer
183266
0.1392%
$18.1118<0.0001%
GAP (Bermuda) LTD10 percent owner
9681818
7.3537%
$18.1110<0.0001%
De Rubertis Francescodirector
3936970
2.9903%
$18.1160<0.0001%
Medicxi Ventures Management (Jersey) Ltd10 percent owner
3936970
2.9903%
$18.1160<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Medicxi Growth I Lp$225.58M17.6619.96M0%+$050.22
General Atlantic$109.4M8.579.68M0%+$02.84
Ecor1 Capital Llc$63.49M4.975.62M0%+$00.45
Vida Ventures Advisors Llc$44.43M3.483.93M0%+$024.68
Perceptive Advisors$34.84M2.733.08MNew+$34.84M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.